The FDA has issued an emergency use authorization (EUA) to Illumina Inc. for its COVID-19 diagnostic test utilizing next generation sequence technology.   The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. Using next generation sequencing means that the test can generate information about the genomic sequence of the virus present in a sample, which ...